Background: This study compares intraocular pressure (IOP)-lowering efficacy and retrobulbar hemodynamic effects of bimatoprost and travoprost in patients with newly diagnosed open-angle glaucoma.
Methods: Patients were randomly assigned to one of two treatment groups (bimatoprost group, n = 36; travoprost group, n = 46). IOP levels were measured with Goldmann applanation tonometer. Peak systolic velocity, end-diastolic velocity and resistivity index were obtained for each vessel by color Doppler imaging.
Results: Both bimatoprost and travoprost significantly lowered IOP on days 30, 90 and 180 (p < 0.001). There was no significance between the 2 drugs on all follow-up visits. End-diastolic velocity of central retinal artery on day 180 was significantly higher than the value obtained at baseline in both groups.
Conclusions: Patients were likely to achieve and maintain low target IOP with both drugs. Both drugs also resulted in improvement in the central retinal artery blood flow.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000112624 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New treatments for glaucoma.
Curr Opin Ophthalmol
January 2025
New York Eye Surgery Center, New York City, New York, USA.
Purpose Of Review: This review highlights new Federal Drug Administration (FDA) approved glaucoma treatments to familiarize providers with immediately available options.
Recent Findings: New FDA-approved treatments include the bimatoprost implant, travoprost implant, direct selective laser trabeculoplasty (DSLT), and ocular pressure adjusting pump. The bimatoprost implant is approved for a single administration with effects lasting for about 1 year, as opposed to the nearly 3-year effect for the travoprost implant.
Systemic adverse drug events to topical prostaglandin analogs for treating glaucoma: a retrospective focused pharmacovigilance study.
BMC Ophthalmol
December 2024
Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain.
Background: Prostaglandin analogs are first-line treatments for open-angle glaucoma due to their proven efficacy in reducing intraocular pressure. Despite their topical administration, systemic adverse drug Events (ADEs) have been reported. This study investigates the systemic ADEs associated with topical prostaglandin analogs using the United States Food and Drug Administration (USFDA) Adverse Drug Event Reporting System (AERS) database.
View Article and Find Full Text PDFChanges in prostaglandin-associated periorbital syndrome: a self-controlled and prospective study.
Cutan Ocul Toxicol
December 2024
Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China.
Article Synopsis
- The study investigated the incidence of the prostaglandin-associated periorbital syndrome (PAPS) in patients with primary open-angle glaucoma or ocular hypertension after using topical prostaglandin analogues (PGAs) for 3-6 months.
- Among the 55 patients studied, key indicators such as interpupillary distance and exophthalmos were measured, alongside subjective assessments of periocular changes, showing significant changes primarily at the 1 and 3-month marks.
- Results indicated that bimatoprost resulted in the highest incidence of PAPS, with noticeable periorbital changes like eyelash growth and hyperpigmentation increasing over time.
Green extraction of prostaglandin analogs in cosmetics using deep eutectic solvents and detection via LC-MS/MS.
J Chromatogr A
January 2025
Advanced Analysis Division, Toxicological Evaluation and Research Department, Ministry of Food and Drug Safety, Osong Health Technology Administration Complex, National Institute of Food and Drug Safety Evaluation, Cheongju-si, Chungcheongbuk-do 28159, Republic of Korea. Electronic address:
Prostaglandin analogs (bimatoprost, travoprost, tafluprost, etc.) have similar effects to prostaglandins and are effective drugs for treating glaucoma. These compounds exhibit abnormal reactions such as causing eyelash growth, with several cases being reported of people purchasing them to increase eyelash growth; however, some cases have reported side effects such as pigmentation and dry eyes.
View Article and Find Full Text PDFAdverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database.
Ther Adv Drug Saf
October 2024
Xiamen University Affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine, Xiamen University, 401 Chengyi Build, Xiang-an Campus of Xiamen University, South Xiang-an Road, Xiamen, Fujian 361005, China.
Article Synopsis
- - The study investigates common adverse events related to four prostaglandin medications used for glaucoma (latanoprost, bimatoprost, travoprost, and tafluprost) using the FDA's Adverse Event Reporting System (FAERS) database.
- - It involves a detailed statistical analysis of adverse event data, revealing that eye disorders, particularly iris hyperpigmentation and corneal irritation, are significant issues associated with these drugs.
- - The findings indicate that adverse events occur differently over time across the medications, with latanoprost leading to longer onset times compared to bimatoprost, although the data can't definitively imply cause and effect.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!